July 26-27, 2019

For Sponsorship Information, Convening Brochure 2019

Registration is now OPEN, 2019 Registration Form

Agenda will be available soon

The aim of the Hope Funds for Cancer Research Scientific Convening is not only to highlight recent exciting advances, but to lay the groundwork for new advances in this field by bringing the best minds in cancer research to facilitate the next golden-age of discoveries and treatments.

cancer cell signaling and transcription
cancer metabolism
RNA, RNAi, mRNA and micro-RNA
precision medicine
gene editing

James Allison, MD Anderson Cancer Center
Imre Bartos, University of FLorida
Joan Brugge, Harvard University
John Byrd, Ohio State University
Carlos Campos, University of Washington
Lewis C. Cantley, Weill Cornell Medical School
Don Cleveland, UC San Diego
George Demetri, Dana-Farber Cancer Institute
Napoleone Ferrara, UCSD
Karuna Ganesh, Memorial Sloan-Kettering Cancer Center
Paul Greengard, Rockefeller University
William C. Hahn, The Broad Institute and Dana-Farber Cancer Institute
Tyler Jacks, Koch Institute for Integrative Cancer Research
William Kaelin, Dana-Farber Cancer Institute
Robert Langer, Koch Institute for Integrative Cancer Research
Carla Kim, Children’s Hospital Boston
Bluma Lesch, Yale University
Leanne Li, Koch Institute for Integrative Cancer Research
Craig Mello, University of Massachusetts Medical School
Malcolm A.S. Moore, Sloan-Kettering Institute
Larry Norton, M.D., Memorial Sloan-Kettering Cancer Center
David C. Page, Whitehead Institute at MIT
Thales Papagiankopoulos, NYU Medical Center
Christopher Pirozzi, Duke University
John Quackenbush, Dana-Farber Cancer Institute
Srivatsan Raghavan, Dana-Farber Cancer Institute
Robert G. Roeder, Rockefeller University
Rajesha Rupaimoole, Beth Israel Deaconess
David Sabatini, Whitehead Institute at MIT
Charles Sawyers, Memorial Sloan-Kettering Cancer Center
Juan Manuel Schvartzman, Memorial Sloan-Kettering

Joan A. Steitz, Yale University
Sohail Tavazoie, Rockefeller University
Craig Thompson, Sloan-Kettering Institute
Tuomas Tammela, Memorial Sloan-Kettering Cancer Center
Robert A. Weinberg, Whitehead Institute at MIT
Bryan R.G. Williams, Hudson Institute of Medical Research
Richard Young, Whitehead Institute at MIT
currently in formation

Lewis C. Cantley, Chairman, Hope Funds for Cancer Research
Leah Rush Cann, Trustee, Hope Funds for Cancer Research
Adrian Hobden, Trustee, Hope Funds for Cancer Research
Andrew Mullen, Advisor, Hope Funds for Cancer Research
Chris Pinault, Development Committee, Hope Funds for Cancer Research
currently in formation

Hope Funds for Cancer Research: Advancing Innovative Research in Understudied Cancers

The Hope Funds for Cancer Research is a non-profit organization (509 (a)(1) charity under 501(c)(3) of the Internal Revenue Service’s code) that was formed in 2006 by individuals with experience in oncology, intellectual property law, investment banking, philanthropy, sociology, and the arts to fund to the most interesting and promising academic research addressing the most difficult-to-treat cancers. Hope Funds for Cancer Research provides fellowships to postdoctoral scientists who propose to work on highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including (but not limited to) pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS. Proceeds from all Hope Funds for Cancer Research activities, including this convening, support our research Fellows.